Journals / Cyprus Journal of Medical Sciences / 2021 / Cilt: 6 - Sayı: 2

Renal Cell Carcinoma: A 10-Year Retrospective Study

Pages
107–111
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION This study found survival to be negatively correlated with grade 4, older age, and treatment method, i.e. post-operative chemotherapy and post-operative radiochemotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND/AIMS This study was conducted to investigate survival and its associated factors in patients with clear cell renal cell carcinoma (CCRCC).
📊
Key Findings & Data:Continuous variables were expressed as mean6SD, and univariate analyses of survival were conducted using the Kaplan–Meier method and log-rank test and multivariate analyses using the Cox regression model.
💡
Conclusion & Impact:CONCLUSION This study found survival to be negatively correlated with grade 4, older age, and treatment method, i.e. post-operative chemotherapy and post-operative radiochemotherapy.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

BACKGROUND/AIMS This study was conducted to investigate survival and its associated factors in patients with clear cell renal cell carcinoma (CCRCC). MATERIAL and METHODS This retrospective study recruited patients diagnosed with CCRCC in Shahid Rahnemoon Hospital, Yazd, Iran, followed them up from their presentation until their death or end of the study and examined their demographic information and clinical and tumor characteristics. Continuous variables were expressed as mean6SD, and univariate analyses of survival were conducted using the Kaplan–Meier method and log-rank test and multivariate analyses using the Cox regression model. RESULTS The study recruited 206 patients, including 132 males, with CCRCC and a mean age of 57.9 6 13.6 years. During the follow up, 53.9% (n ¼ 111) of the patients survived and data regarding the survival status of 24.3% (n ¼ 50) patients were missing. The mean survival duration was obtained as 59.9 6 2.7 months. The independent survival indicators were grade 4 (HR: 2.4, 95% CI: 0.4-5.7, P ¼ .02), older age (HR: 4.14, 95% CI: 1.7-8.4, P ¼ .02), and treatment method includes post-operative chemotherapy (HR: 4.9, 95% CI: 1.7-10.8, P ¼ .004) and postoperative radiochemotherapy (HR: 8.4, 95% CI: 1.9-16.2, P ¼ .03). CONCLUSION This study found survival to be negatively correlated with grade 4, older age, and treatment method, i.e. post-operative chemotherapy and post-operative radiochemotherapy.

🔖

Cite This Article

ZAHİR, S. T., HEİDARYMEYBODİ, Z., HERMAN, M. (2021). Renal Cell Carcinoma: A 10-Year Retrospective Study. Cyprus Journal of Medical Sciences, Cilt: 6 - Sayı: 2, 107–111. https://ajindex.com/articles/418166

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019
  2. 75(1):74-84. [CrossRef] 2. Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011
  3. 60(4):615-621. [CrossRef] 3. DeCastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin N Am. 2008
  4. 35(4):581-592. [CrossRef] 4. Hedgire SS, Elmi A, Nadkarni ND, Cao K, McDermott S, Harisinghani MG. Preoperative evaluation of perinephric fat invasion in patients with renal cell carcinoma: Correlation with pathological findings. Clin Imaging. 2013
  5. 37(1):91-96. [CrossRef] 5. Petejova N, Martinek A. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomed Papers Med Fac Palacky Univ Olomouc. 2016
  6. 160(2):183-194. [CrossRef] 6. Grignon DJ, Che M. Clear cell renal cell carcinoma. Clin Lab Med. 2005
  7. 25(2):305-316. [CrossRef] 7. Vaishampayan U, Do H, Hussain M, Schwartz K. Racial disparity in incidence patterns and outcome of kidney cancer. Urology. 2003
  8. 62(6):1012-1017. [CrossRef] 8. Dall’Oglio MF, Ribeiro-Filho LA, Antunes AA, et al. Microvascular tumor invasion, tumor size and Fuhrman grade: A pathological triad for prognostic evaluation of renal cell carcinoma. J Urol. 2007
  9. 178(2):425-428. [CrossRef] 9. Karakiewicz PI, Jeldres C, Suardi N, et al. Age at diagnosis is a determinant factor of renal cell carcinoma–specific survival in patients treated with nephrectomy. Can Urol Assoc J. 2008
  10. 2(6):610. [CrossRef] 10. Thompson RH, Ordonez MA, Iasonos A, et al. Renal cell carcinoma in young and old patients—Is there a difference? J Urol. 2008
  11. 180(4):1262-1266. [CrossRef] 11. Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: A trend analysis. Eur Urol. 2011
  12. 59(1):135-141. [Cross- Ref] 12. Harris WB. Biomarkers for evaluating racial disparities in clinical outcome in patients with renal cell carcinoma. Mol Aspects Med. 2015
  13. [CrossRef] 13. Lucca I, Klatte T, Fajkovic H, De Martino M, Shariat SF. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol. 2015
  14. 12(10):585. [CrossRef] 14. Feng X, Zhang L, Tu W, Cang S. Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: A SEER-based analysis. Medicine. 2019
  15. 98(31):e16684. [CrossRef] 15. Moch H, Humphrey PA, Ulbright TM, Reuter VE.